California Public Employees Retirement System Sells 10,073 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

California Public Employees Retirement System lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 240,178 shares of the biopharmaceutical company’s stock after selling 10,073 shares during the quarter. California Public Employees Retirement System owned approximately 0.18% of Halozyme Therapeutics worth $8,877,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Artisan Partners Limited Partnership increased its stake in shares of Halozyme Therapeutics by 3.4% in the third quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after buying an additional 253,363 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Halozyme Therapeutics by 0.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,698,359 shares of the biopharmaceutical company’s stock valued at $64,877,000 after buying an additional 15,902 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Halozyme Therapeutics by 174.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after buying an additional 563,989 shares during the period. Kennedy Capital Management LLC increased its stake in shares of Halozyme Therapeutics by 4.7% in the third quarter. Kennedy Capital Management LLC now owns 646,475 shares of the biopharmaceutical company’s stock valued at $24,695,000 after buying an additional 28,880 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Halozyme Therapeutics by 10.9% in the third quarter. Principal Financial Group Inc. now owns 590,651 shares of the biopharmaceutical company’s stock valued at $22,563,000 after buying an additional 58,123 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,196,800 in the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $39.82 on Friday. The company has a market cap of $5.06 billion, a price-to-earnings ratio of 18.87, a price-to-earnings-growth ratio of 0.44 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52 week low of $29.85 and a 52 week high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The firm has a 50 day moving average of $40.00 and a 200-day moving average of $37.87.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HALO shares. The Goldman Sachs Group lowered their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.